Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: A case with long-term follow-up
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
An association of antiphospholipid antibody syndrome with antibodies directed against either phospholipids or plasma proteins strongly suggest that B-cell dysfunction may be involved in its pathogenesis. Antiphospholipid antibody syndrome with autoimmune cytopenias shows a poor response rate to conventional treatment with anticoagulants, glucocorticosteroids, immunosuppressive agents, intravenous immunoglobulin or plasmapheresis. We report a case of life-threatening antiphospholipid antibody syndrome with Evans syndrome receiving successful multimodal treatment including anti-CD20 monoclonal antibody rituximab with long-term follow-up.
Details
Original language | English |
---|---|
Pages (from-to) | 757-760 |
Number of pages | 4 |
Journal | Lupus |
Volume | 17 |
Issue number | 8 |
Publication status | Published - 2008 |
Peer-reviewed | Yes |
External IDs
PubMed | 18625656 |
---|
Keywords
ASJC Scopus subject areas
Keywords
- Antiphospholipid antibody syndrome, Hemolytic anemia, Rituximab, Thrombocytopenia